Cat. No.: HY-P99355

Biologically Validated

Bimagrumab

Name: Bimagrumab
Brand: MedChemExpress
SKU: HY-P99355
Price: 400.00 USD
Availability: InStock
Rating: 5 (3 reviews)

(Synonyms: Anti-ACVR2B Reference Antibody; BYM338)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Bimagrumab (Anti-ACVR2B Reference Antibody; BYM338) is a monoclonal antibody targeting activin type II receptors (ActRII). Bimagrumab binds to human ActRIIB (K_d 1.7 pM) and ActRIIA (K_d 434 pM), blocks ligand binding and downstream Smad activation, and inhibits myostatin/activin A-induced Smad phosphorylation. Bimagrumab induces skeletal muscle hypertrophy in an Akt-independent manner via mTOR-mediated muscle protein synthesis, increases muscle mass and strength, promotes myoblast differentiation/fusion, prevents myotube atrophy and glucocorticoid-induced muscle loss, reduces fat mass and fat depot weight/adipocyte size, inhibits adipose inflammation, induces fat oxidation, preserves lean body mass during incretin-induced weight loss, and enhances the appetite-suppressive effect of incretins. Bimagrumab can be used in research on obesity and skeletal muscle atrophy and weakness.

For research use only. We do not sell to patients.

Purity : 99.31%
CAS No.: 1356922-05-8
Molecular Weight:142.78 kDa

Storage:

Shipping with dry ice

Please store the product under the recommended conditions in the Certificate of Analysis.

Bimagrumab Chemical Structure

CAS No.: 1356922-05-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
- Verified Bioactivity
Chemical Information
Publications (3)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

Human IgG1 (L234A/L235A) lambda2

Recommend Isotype Controls

Human IgG1 (L234A/L235A) lambda2, Isotype Control

Species Reactivity

Human

In Vitro

Cytokines and ChemokinesOthers

Cytokines and Chemokines

Bimagrumab (24 h) inhibits myostatin- and activin A-induced Smad2/3 luciferase signaling in HEK293T cells with IC₅₀ values of 154 pM and 343 pM, respectively^[4].
Bimagrumab (4 days) enhances primary human skeletal myoblast differentiation and reverses myostatin/activin A inhibition, with IC₅₀ values of 519 pM and 3,105 pM in the CK differentiation assay^[4].
Bimagrumab (30 μg/mL; 2-72 h) prevents myostatin- and activin A-induced atrophy and Smad2/3 activation in human primary myotubes^[4].

Others

Bimagrumab binds human ActRIIB with a K_D of 1.7 pM and human ActRIIA with a K_D of 434 pM by SET^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lipid MetabolismCarbohydrate MetabolismCytokines & ChemokinesMitochondrial Oxidative PhosphorylationProtein/Amino Acid MetabolismOthers

Lipid Metabolism

Carbohydrate Metabolism

Cytokines & Chemokines

Bimagrumab (20 mg/kg; s.c.; once weekly; 14 days) increases lean mass and skeletal muscle size while reducing fat mass and adipose depot weights in diet-induced obese mice^[1].

Lipid Metabolism

Cytokines & Chemokines

Bimagrumab (20 mg/kg; s.c.; once weekly; 14 days) plus Semaglutide (HY-114118) (120 µg/kg; s.c.; once daily; 14 days) enhances fat mass loss while preserving lean mass and skeletal muscle weights in diet-induced obese mice^[1].

Mitochondrial Oxidative Phosphorylation

Protein/Amino Acid Metabolism

Bimagrumab (6-20 mg/kg; s.c.; once weekly; 4 weeks) induces skeletal muscle hypertrophy in naive SCID mice, increasing body weight and muscle mass across muscle types^[4].

Protein/Amino Acid Metabolism

Bimagrumab (5-20 mg/kg/week; s.c.; weekly; 14 days) prevents glucocorticoid-induced skeletal muscle atrophy and weakness in mice^[4].

Protein/Amino Acid Metabolism

Lipid Metabolism

Bimagrumab increases muscle fiber size by 10-15% in murine models and promotes muscle growth and metabolic/incretin-enhancing effects in obese mice^[2].

Others

Bimagrumab (20 mg/kg; s.c.; once weekly; 14 days) increases skeletal muscle weights in M-AktDKO mice, indicating Akt-independent muscle hypertrophy downstream of ActRII blockade^[1].
Bimagrumab (20 mg/kg; i.p.; once weekly; 3 weeks) increases 3-week weight loss to -14.5 g and achieves 96.4% weight-loss quality when added to Tirzepatide (HY-P1731) in diet-induced obese mice^[3].
Bimagrumab (20 mg/kg; i.p.; once weekly; 3 weeks) increases 3-week weight loss to -9.8 g and achieves 104.6% weight-loss quality when added to Semaglutide in diet-induced obese mice^[3].
Bimagrumab (20 mg/kg; i.p.; once weekly; 3 weeks) increases 3-week weight loss to -4.5 g and achieves 122.8% weight-loss quality when added to liraglutide in diet-induced obese mice^[3].
Bimagrumab (20 mg/kg; s.c.; days 0, 7, 14, 21, and 28) increases body weight, lean mass, and muscle weight in wild-type mice^[4].
Bimagrumab (20 mg/kg; s.c.; days 0, 7, 14, 21, and 28) increases body weight, lean mass, and muscle weight in myostatin-deficient MstnLn/Ln mice^[4].
Bimagrumab (5-20 mg/kg; i.p.; days 21, 23, and 28) enhances recovery from glucocorticoid-induced skeletal muscle atrophy in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57Bl/6J background (male, 24-25 weeks, diet-induced obese)^[1]
Dosage:

20 mg/kg
Administration:

s.c.; once weekly; 14 days
Result:

Decreased fat mass by approximately 30% and increased lean mass by approximately 8%.
At day 14, adipose depot weights were iWAT 1.339 g, eWAT 1.122 g, rpWAT 0.481 g, and BAT 0.281 g.
Average adipocyte size was decreased in iWAT and eWAT.
Skeletal muscle weights were TA 64.39 mg, EDL 16.89 mg, soleus 12.89 mg, and gastrocnemius 202.44 mg.
Skeletal muscle size increased by approximately 10-20% across all four muscles.
TA muscle fiber cross-sectional area was larger than in control mice.
Fed blood glucose was modestly elevated, plasma insulin trended lower, adiponectin was comparable, leptin trended lower, IL-6 and MCP-1 trended lower, and circulating glycerol and free fatty acids were reduced.
Exercise performance showed VO2 max 4.83 mL/min (18% improvement) and time to exhaustion 682.0 s; the VO2 max effect was lean-mass dependent by ANCOVA.

Animal Model:

C57Bl/6J background (male, 24-25 weeks, diet-induced obese)^[1]
Dosage:

20 mg/kg
Administration:

s.c.; once weekly (bimagrumab); once daily (semaglutide); 14 days
Result:

Combination administration produced greater than 25% body weight loss and 70% fat mass loss.
Lean mass proportion was indistinguishable from control at day 13, indicating preservation of lean mass despite reduced food intake.
At day 14, adipose depot weights were iWAT 0.606 g, eWAT 0.589 g, rpWAT 0.203 g, and BAT 0.174 g; eWAT, iWAT, and rpWAT showed greater than 60% reductions relative to control.
Adipocyte size was smallest in the combination group.
Skeletal muscle weights were TA 58.69 mg, EDL 14.88 mg, soleus 11.38 mg, and gastrocnemius 184.63 mg, comparable to control.
Adiponectin increased compared with semaglutide alone, leptin decreased compared with control, IL-6 and MCP-1 trended lower, and circulating glycerol and free fatty acids were reduced.
Exercise performance showed VO2 max 4.61 mL/min (13% average improvement) and time to exhaustion 760.5 s.

Animal Model:

Akt1 loxp/loxp;Akt2 loxp/loxp with ACTA1-Cre (M-AktDKO; male, 4-6 months) and control mice^[1]
Dosage:

20 mg/kg
Administration:

s.c.; once weekly; 14 days
Result:

In control mice, TA, EDL, soleus, and gastrocnemius weights increased to 52.64 mg, 12.61 mg, 7.89 mg, and 148.5 mg, respectively.
In M-AktDKO mice, TA, EDL, soleus, and gastrocnemius weights were 32.52 mg, 8.43 mg, 5.58 mg, and 99.41 mg, respectively; EDL and gastrocnemius were larger than in M-AktDKO mice, and TA and soleus trended larger.
The percent increase in muscle weights was 17-27% in control mice and 11-23% in M-AktDKO mice.

Animal Model:

C57BL/6J (5-6 weeks of age at diet initiation; average body weight 54 g at start of dosing)^[3]
Dosage:

20 mg/kg
Administration:

i.p. once weekly for 3 weeks; s.c. daily for 3 weeks
Result:

Three-week weight loss increased to -14.5 g when combined with tirzepatide.
Weight-loss quality in combination was 96.4%.

Animal Model:

C57BL/6J (5-6 weeks of age at diet initiation; average body weight 54 g at start of dosing)^[3]
Dosage:

20 mg/kg
Administration:

i.p. once weekly for 3 weeks; s.c. daily for 3 weeks
Result:

Three-week weight loss increased to -9.8 g when combined with semaglutide.
Weight-loss quality in combination was 104.6%.
Fat mass loss greater than 100% of total weight loss reflected additive fat mass loss and muscle mass gain.

Animal Model:

C57BL/6J (5-6 weeks of age at diet initiation; average body weight 54 g at start of dosing)^[3]
Dosage:

20 mg/kg
Administration:

i.p. once weekly for 3 weeks; s.c. twice daily for 3 weeks
Result:

Three-week weight loss increased to -4.5 g when combined with liraglutide.
Weight-loss quality in combination was 122.8%.
Fat mass loss greater than 100% of total weight loss reflected additive fat mass loss and muscle mass gain.

Animal Model:

CB17/ICR-Prkdcscid/Crl (SCID; female; 10 weeks old)^[4]
Dosage:

6 mg/kg; 20 mg/kg
Administration:

s.c.; once weekly; 4 weeks
Result:

Increased body weight and skeletal muscle mass in all examined muscles, including slow, fast, and mixed muscles, in a dose-dependent manner.
Maximal muscle increases reached 25% to 50% depending on the muscle.
The fiber cross-sectional area distribution of gastrocnemius/plantaris increased, reflecting increased individual fiber diameter without changes in fiber number.
Fiber type composition was not altered.
Microarray analysis after 4 weeks at 20 mg/kg identified 58 differentially regulated genes: 47 upregulated and 11 downregulated.
Igf1 was upregulated with a log2 fold change of 0.98 (Table 1).
Pathway analysis suggested extracellular matrix remodeling and downregulation of translation and oxidative phosphorylation.

Animal Model:

C57BL/6J (wild-type; male; 15 to 20 weeks old)^[4]
Dosage:

20 mg/kg
Administration:

s.c.; days 0, 7, 14, 21, and 28
Result:

Increased body weight, lean body mass, and muscle weight in wild-type mice.

Animal Model:

C57BL/6J-Mstnlean/J (MstnLn/Ln; male; 15 to 20 weeks old)^[4]
Dosage:

20 mg/kg
Administration:

s.c.; days 0, 7, 14, 21, and 28
Result:

Increased body weight, lean body mass, and muscle weight in MstnLn/Ln mice.

Animal Model:

C57BL/6 (male; 4 months old)^[4]
Dosage:

5 mg/kg/week; 20 mg/kg/week; 5 or 20 mg/kg (i.p.; days 0, 2, and 7)
Administration:

s.c.; weekly; 14 days; i.p. on days 0, 2, and 7
Result:

Prevented dexamethasone-induced loss of muscle mass, tetanic force, and fiber cross-sectional area.
Dexamethasone-induced tetanic force loss of more than 20% was fully reversed.
Reduced dexamethasone-induced MAFbx and MuRF1 mRNA expression.

Animal Model:

C57BL/6 (male; 4 months old)^[4]
Dosage:

5 mg/kg; 20 mg/kg
Administration:

i.p.; days 21, 23, and 28
Result:

Recovery of skeletal muscle mass in gastrocnemius/plantaris and tibialis cranialis muscles was dose-dependently enhanced after 3 weeks of dexamethasone exposure and dexamethasone withdrawal.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Gene ID

93 [NCBI]

Accession

Q13705

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 lambda

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized ACVR2B Protein, Human can bind Bimagrumab. The EC₅₀ for this effect is 8.254 ng/mL.
Flow cytometric analysis of 10⁶ Jurkat cells with Bimagrumab (HY-P99355, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control.

Chemical Information

CAS No. 1356922-05-8
Appearance Liquid
Molecular Weight 142.78 kDa
Color Colorless to light yellow
SMILES

[Bimagrumab]
Synonyms

Anti-ACVR2B Reference Antibody; BYM338
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (3)

All IFIn Vivo Efficacy StudyWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Diabetes reshapes pancreatic cancer-associated endothelial niche by accelerating senescence. [Abstract]

2025 Sep 30;16(1):8654. PMID: 41027967

Bimagrumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

Pancreatic tumor samples from chow (n = 6 mice per group) and diabetic (n = 9 mice per group) KPC tumor-bearing mice treated with IgG, bimagrumab, or bimagrumab+metformin. The results showed that two injections of bimagrumab (20 mg/kg, subcutaneously, once weekly) reduced tumor burden in diabetic mice.

Bimagrumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

Phosphorylated Smad2 levels and total Smad2 expression were detected via western blotting in KPC tumors from the chow and diabetic mice treated with IgG or bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks) (n=3 mice per group).

Bimagrumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

Representative images of picrosirius red staining (red) in tumors from chow and diabetic KPC tumor-bearing mice treated with IgG or bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks) (n = 6 mice per group).
Nat Commun

Molecular mechanism of Activin receptor inhibition by DLK1. [Abstract]

2025 Jul 1;16(1):5976. PMID: 40593645

Bimagrumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 1;16(1):5976. [Abstract]

Representative microscopy images showing C2C12 myoblast differentiation in the presence of Myostatin, soluble DLK1 + Myostatin, Bimagrumab + Myostatin, or Bimagrumab + soluble DLK1 + Myostatin. Control cells were allowed to differentiate for 72h. Myostatin treatment (4 µg/ml) inhibits C2C12 myoblast differentiation into myotubes as determined by MyoHC staining. Bimagrumab (100 nM) and soluble DLK1 (2 μM) reverse the effect of myostatin on C2C12 differentiation, with no additive effect of adding soluble DLK1 to Bimagrumab treated cells. C2C12 cells were fixed with 4% PFA, immunostained with an anti-MyoHC antibody and an anti-mouse Alexa Fluor 488 secondary antibody. Nuclei were counterstained with Hoechst 33342. Nuclei represented with pseudo color (magenta). The images are representative of one out of two imaging wells per treatment from one experiment. The experiment was independently repeated two times. Scale bar, 100 μm.
Mol Metab

Antibody Blockade of Activin Type II Receptors Preserves Skeletal Muscle Mass and Enhances Fat Loss During GLP-1 Receptor Agonism. [Abstract]

2024 Feb:80:101880. PMID: 38218536

Bimagrumab purchased from MedChemExpress. Usage Cited in: Mol Metab. 2024 Feb:80:101880. [Abstract]

Bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks). Representative TA sections stained with H&E (20x magnification, scale bar = 100 um).

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (293 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Nunn E, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular metabolism. 2024 Feb;80:101880. [Content Brief]

[2]. Kaiser M, et al. Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss. Cardiology in review. 2025 Nov 03. [Content Brief]

[3]. Kevin Nguyen, et al. OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model. Journal of the Endocrine Society, Volume 7, Issue Supplement_1, October-November 2023, bvad114.009.

[4]. Lach-Trifilieff E, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Molecular and cellular biology. 2014 Feb;34(4):606-18. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Bimagrumab

Publications Citing Use of MedChemExpress (MCE) Bimagrumab